News

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.
Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...
The regulator had asked Sarepta Therapeutics to halt all shipments of its therapy, Ele­vidys, after three patients died from ...
The drop comes the day after the drugmaker said it would add a so-called black-box warning to its gene therapy Elevidys after ...
Shares of Sarepta Therapeutics plummeted nearly 30% premarket Friday following a report that a third patient has died during ...
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
Sarepta Therapeutics stock soared over 30% after the pharmaceutical company said it would lay off about 500 employees. It ...